23andMe to 'Experiment' with Different Price Models in 2011
January 05, 2011
23andMe to 'Experiment' with Different Price Models in 2011
"We plan to experiment with various pricing structures a bit in the coming weeks or months," a 23andMe spokesperson told PGx Reporter recently. "We know that our price point has been a barrier for some people in the past."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- 2010 in Review: Genomic Medicine Experiences Growing Pains of Regulation, Economics, and Litigation
January 12, 2011 / Pharmacogenomics Reporter - DTC Genomics Gets Time Before FDA as Agency Considers Regulatory Strategy
July 21, 2010 / Pharmacogenomics Reporter - As Congress Investigates DTC Genomics Market, Firms Vow Cooperation
May 26, 2010 / Pharmacogenomics Reporter - Pathway's Deal with OptumHealth Yields Lowest-Priced Gene Scans in DTC Genomics Industry
November 18, 2009 / Pharmacogenomics Reporter - With Decode Purchase, Amgen Gains Genetics Expertise, Consumers Lose DTC Testing Option
December 12, 2012 / Pharmacogenomics Reporter